tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Paul Matteis, 246 are a BUY (69.3%), 109 are a HOLD (30.7%).
Analyst Paul Matteis, currently employed at STIFEL, carries an average stock price target met ratio of 54.28% that have a potential upside of 42.56% achieved within 230 days.
Paul Matteis’s has documented 693 price targets and ratings displayed on 44 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on VRTX, Vertex Pharmaceuticals at 17-Feb-2026.
Analyst best performing recommendations are on AVDL (AVADEL PHARMACEUTICALS PLC).
The best stock recommendation documented was for AVDL (AVADEL PHARMACEUTICALS PLC) at 5/26/2022. The price target of $2 was fulfilled within 1 day with a profit of $0.93 (86.92%) receiving and performance score of 869.16.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 08-Dec-2021
$23
$-0.99 (-4.13%)
$22
21 days ago
(06-Feb-2026)
17/17 (100%)
$-0.56 (-2.38%)
84
Buy Since 26-Jun-2025
$31
$7.01 (29.22%)
$32
24 days ago
(03-Feb-2026)
0/5 (0%)
$6.24 (25.20%)
Buy Since 21-Oct-2025
$36
$12.01 (50.06%)
$33
1 months 21 days ago
(06-Jan-2026)
0/2 (0%)
$9.06 (33.63%)
Buy Since 17-Oct-2023
$40
$16.01 (66.74%)
$39
1 months 21 days ago
(06-Jan-2026)
2/7 (28.57%)
$13.06 (48.48%)
467
Hold Since 03-Nov-2022
$25
$1.01 (4.21%)
2 months 16 days ago
(11-Dec-2025)
18/21 (85.71%)
$-1.68 (-6.30%)
118
Which stock is Paul Matteis is most bullish on?
Which stock is Paul Matteis is most reserved on?
What Year was the first public recommendation made by Paul Matteis?
